Dong‐Hyun Choi

ORCID: 0000-0003-0334-9809
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Drug Transport and Resistance Mechanisms
  • Pharmacogenetics and Drug Metabolism
  • Cardiac Imaging and Diagnostics
  • Coronary Interventions and Diagnostics
  • Pharmacological Effects and Toxicity Studies
  • Inflammatory Biomarkers in Disease Prognosis
  • Venous Thromboembolism Diagnosis and Management
  • Acute Myocardial Infarction Research
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Cardiac Arrhythmias and Treatments
  • Cardiac electrophysiology and arrhythmias
  • Antibiotics Pharmacokinetics and Efficacy
  • Cardiac Valve Diseases and Treatments
  • Atrial Fibrillation Management and Outcomes
  • Cardiac pacing and defibrillation studies
  • Cardiovascular Health and Disease Prevention
  • Cardiovascular Disease and Adiposity
  • Protease and Inhibitor Mechanisms
  • Drug-Induced Hepatotoxicity and Protection
  • Pharmacological Effects of Natural Compounds
  • Transplantation: Methods and Outcomes
  • Coronary Artery Anomalies
  • Lipoproteins and Cardiovascular Health
  • Diabetes Treatment and Management
  • Cardiac tumors and thrombi

Yonsei University
2024-2025

Chosun University
2015-2024

Chosun University Hospital
2015-2023

Stanford University
1991-2018

Stanford Medicine
1991-2018

Cardiovascular Institute of the South
2017-2018

Ajou University
2017

University of Florida
2016

Columbus Oncology and Hematology Associates
2016

Seoul National University Hospital
2008-2010

We performed transesophageal echocardiography in 50 consecutive hospitalized patients with recent transient ischemic attack or stroke of embolic origin to determine whether is more sensitive than transthoracic detection possible intracardiac sources embolism. Twenty-six a negative echocardiogram for potential source emboli had study that demonstrated at least one abnormality. Abnormalities noted by included five either left atrial appendage clot, four patent foramen ovale, and nine...

10.1161/01.str.22.6.734 article EN Stroke 1991-06-01

Platelet size, measured as mean platelet volume (MPV), is associated with reactivity. MPV has been identified an independent risk factor for future stroke and myocardial infarction. The aim of this study was to determine the association development stoke in patients atrial fibrillation (AF). MPV, N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP) were analysed 200 AF (mean age 69 years; 56% male). primary endpoint ischaemic event. 8.5 ± 1.0 fL...

10.3109/09537104.2011.560306 article EN Platelets 2011-05-23

The influence of various process conditions on the structural integrity and electrical properties Al∕HfO2∕p-In0.13Ga0.87As metal-oxide-semiconductor capacitors was investigated. Room temperature capacitance voltage measurements revealed postdielectric deposition anneal reduced hysteresis by more than 0.5V sulfur passivation InGaAs improved frequency dispersion as well interface trap density. At V=VFB−1V, leakage current densities ∼1.3×10−7, 0.4×10−6, 1.3×10−6A∕cm2 were measured in devices...

10.1063/1.2363959 article EN Applied Physics Letters 2006-10-16

The aim of this study was to determine the association mean platelet volume (MPV) with development stroke or coronary artery disease (CAD) in diabetes mellitus (DM). MPV analyzed 200 Korean patients DM. primary endpoint composite ischemic stroke/CAD events. 7.6 ± 0.8 fl. There were 14 events and 8 CAD during a 28.4 months follow-up. Kaplan–Meier analysis revealed that higher tertile group (≥7.9 fl) had significantly rate compared lower (≤7.3 (29.9% vs. 2.8%, log-rank: p < 0.001). Higher an...

10.3109/09537104.2012.710858 article EN Platelets 2012-08-07

Epidemiological studies have suggested that elevated concentrations of particulate matter (PM) are strongly associated with the incidence atherosclerosis, however, underlying cellular and molecular mechanisms atherosclerosis by PM exposure components mainly responsible for this adverse effect remain to be established. In investigation, we evaluated effects ambient on vascular smooth muscle cell (VSMC) behavior. Furthermore, polycyclic aromatic hydrocarbons (PAHs), major PM, VSMC migration...

10.1186/s12989-022-00472-z article EN cc-by Particle and Fibre Toxicology 2022-04-22

Objective: In previous studies, echogenic liposomes with liquid and gas cores were analyzed as alternative carriers of drug molecules cavitation nuclei for sonoporation. The possibility small interfering RNA (si-RNA) encapsulation has also been presented. this study, the usability seeds was evaluated using an in vivo model. Methods: A doxorubicin-loaded liposome synthesized a carrier. size distribution number formed measured. Five comparative experiments conducted without liposomes, results...

10.3390/pharmaceutics17040509 article EN cc-by Pharmaceutics 2025-04-11

Background/Aims: Proprotein-converting enzyme subtilisin-kexin type 9 (PCSK9) inhibitors act more promptly and efficiently than statins reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). This study aimed to assess short-term effects perioperative administration a single-dose PCSK9 inhibitor ACS. Methods: included 789 consecutive undergoing percutaneous intervention (PCI) for The primary clinical endpoint was occurrence major adverse (MACEs) within one...

10.3904/kjim.2024.363 article EN cc-by-nc The Korean Journal of Internal Medicine 2025-04-30

Abstract Verapamil is known to be a P‐glycoprotein (P‐gp) substrate and norverapamil formed via hepatic cytochrome P450 (CYP 3A) in the rat. Epigallocatechin gallate (EGCG), flavonoid, was reported an inhibitor of both P‐gp CYP3A. Hence, it could expected that EGCG alter pharmacokinetics verapamil. In this study, 9 mg/kg verapamil administered orally Sprague–Dawley rats 30 min after oral administration 2 10 EGCG. Compared with controls, AUC values (74.3% 111% increase for EGCG, respectively)...

10.1002/bdd.644 article EN Biopharmaceutics & Drug Disposition 2009-02-19

Abstract Objectives The effects of myricetin, a natural flavonoid, on the pharmacokinetics losartan and its active metabolite, EXP-3174, were investigated in rats. Losartan myricetin interact with cytochrome P450 (CYP) enzymes P-glycoprotein, increase use health supplements may result being taken concomitantly as combination therapy to treat or prevent cardiovascular diseases. Methods pharmacokinetic parameters EXP-3174 determined after oral administration (9 mg/kg) rats presence absence...

10.1211/jpp.62.07.0012 article EN Journal of Pharmacy and Pharmacology 2010-07-01

We hypothesized that the combination of a high neutrophil to lymphocyte ratio (NLR) and mean platelet volume (MPV) would be stronger predictor future cardiovascular events after percutaneous coronary intervention (PCI). Both NLR MPV were measured in 364 consecutive patients undergoing PCI. The primary end point was incidence major adverse (MACEs), including cardiac death, nonfatal myocardial infarction, stent thrombosis. median values 2.8 8.2 fL, respectively. There 26 MACEs during follow-up...

10.1177/0003319718768658 article EN Angiology 2018-04-09

The purpose of this study was to investigate the effects resveratrol, an antioxidant, on pharmacokinetics diltiazem and its active metabolite, desacetyldiltiazem, in rats. pharmacokinetic parameters desacetyldiltiazem were determined after oral administration (15 mg/kg) rats presence absence resveratrol (0.5, 2.5, 10 mg/kg). Compared control group, significantly ( P &lt; 0.05) increased area under plasma concentration–time curve (AUC) diltiazem, except for 0.5 mg/kg. Consequently, absolute...

10.1111/j.1755-5922.2008.00060.x article EN Cardiovascular Therapeutics 2008-11-11

The present study was designed to investigate the effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (atorvastatin, pravastatin, simvastatin) on pharmacokinetics losartan and its active metabolite EXP-3174 in rats. Pharmacokinetic parameters rats were determined after oral intravenous administration (9 mg/kg) without with HMG-CoA (1 mg/kg). effect P-gp cytochrome (CYP) 3A4 activity also evaluated. Atorvastatin, pravastatin simvastatin inhibited CYP3A4 activities...

10.1159/000328773 article EN Pharmacology 2011-01-01

The aim of this study was to determine the associations mean platelet volume (MPV) with development adverse outcomes after percutaneous coronary intervention (PCI) and reactivity. MPV function testing were analysed in 208 patients who underwent PCI. primary endpoint cardiac death. secondary cardiovascular events (CVE): composite myocardial infarction (MI), target vessel revascularization (TVR), stent thrombosis (ST). median level, aspirin reaction unit (ARU), P2Y12 units (PRU) P2Y12%...

10.3109/09537104.2013.821606 article EN Platelets 2013-08-02

The aim of this study was to determine the associations mean platelet volume (MPV) high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B type natriuretic peptide (NT-proBNP) with development adverse outcomes after percutaneous coronary intervention (PCI). MPV hs-cTnT NT-proBNP were analyzed in 372 patients who underwent PCI. primary endpoint death. secondary cardiovascular events (CVE): composite death, myocardial infarction (MI), target vessel revascularization (TVR), ischemic...

10.3109/09537104.2013.835393 article EN Platelets 2013-10-08

This study was designed to establish the relationship of high-sensitivity C-reactive protein (hsCRP) and mean platelet volume (MPV) with development adverse outcomes after percutaneous coronary intervention (PCI). hsCRP levels MPV were analysed in 372 patients who underwent PCI, primary endpoint as major cardiac cerebrovascular events (MACCE): a composite death, myocardial infarction (MI), target vessel revascularization (TVR), ischemic stroke stent thrombosis. During follow-up period (mean,...

10.1097/mbc.0000000000000398 article EN Blood Coagulation & Fibrinolysis 2015-09-02

The purpose of this study was to investigate the possible effects licochalcone A (a herbal medicine) on pharmacokinetics nifedipine and its main metabolite, dehydronifedipine, in rats. pharmacokinetic parameters and/or dehydronifedipine were determined after oral intravenous administration rats absence (control) presence (0.4, 2.0 10 mg/kg). effect P-glycoprotein (P-gp) cytochrome P450 (CYP) 3A4 activity also evaluated. Nifedipine mainly metabolized by CYP3A4. Licochalcone inhibited CYP3A4...

10.1002/bdd.1905 article EN Biopharmaceutics & Drug Disposition 2014-06-06

The aim of the present study was to evaluate relationship between thyroid hormone levels and infarct severity in patients with ST-elevation myocardial infarction (STEMI).We retrospectively reviewed levels, severity, extent transmurality 40 STEMI evaluated via contrast-enhanced cardiac magnetic resonance imaging.The high triiodothyronine (T3) group (≥ 68.3 ng/dL) exhibited a significantly higher transmural involvement (late enhancement > 75% after administration gadolinium contrast agent)...

10.3904/kjim.2014.29.4.454 article EN cc-by-nc The Korean Journal of Internal Medicine 2014-01-01
Coming Soon ...